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1. Objectives and Study 
Nocturnal enuresis affects 10% of the 7-year-old children and is 
essentially caused by a mismatch between nocturnal bladder 
capacity and the amount of urine produced during the night 
together with failure of the child to awaken in response to a full 
bladder. 
 
Urine overproduction at night or nocturnal polyuria (NP) is a 
major factor contributing to monosymptomatic nocturnal 
enuresis (MNE) pathophysiology in a large proportion of 
patients.3 Since NP is related to an abnormal circadian rhythm of 
arginine vasopressin (AVP) secretion, the synthetic AVP analogue 
desmopressin is widely used to treat MNE.4 
 
Baeyens et al5 demonstrated an increased prevalence of 
attention deficit-hyperactivity disorder (ADHD) in children with 
MNE. According to Dhondt et al6 there is a high incidence of 
periodic limb movements in sleep at night in children with 
nocturnal enuresis. Those children have an increased cortical 
arousability leading to awakening. The frequent awakening most 
likely has an influence on concentration and other ADHD-
symptoms in daily life. 
 
This study will assess the impact of desmopressin melt on: 
 - ADHD-symptoms 
 - cognition and learning 
-  sleep 
-  quality of life 
-  self esteem.  
 
Patients aged 6-16 years with MNE according to the ICCS -
criteria, who experience at least 4/7 wet days with proven 
nocturnal polyuria, defined as nocturnal diuresis >100% bladder 
volume for age on at least 4/7days. 
 
Exclusion criteria are: daytime incontinence resistant to therapy, 
dysfunctional voiding, poor therapy-compliance, diuretics, 
antihypertensives, uropathy, renal abnormalities. 
 
Patients are tested before the start of the study medication and 
6 months later. Study medication is the oral lyophylisate 
formulation of desmopressin (melt) at a starting dose of 120µg. 
If not treatment is not successfull after 1 month, dose could be 
titrated up to 240µg.  
 
It is a multi-method, multi-informant study. Using 
polysomnography, questionnaires, interviews and 
neuropsychological testing.  
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Inclusion is now finished. Results will be expected in September 
2012.  
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